ETFs with UTHR as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|5.35%||First Trust Amex Biotechnology Index Fund (FBT)||+2.33 (3.65%)|
|2.42%||First Trust Health Care AlphaDEX (FXH)||+4.23 (10.04%)|
|2.39%||SPDR Series Trust SPDR S&P Biotech ETF (XBI)||+2.76 (2.29%)|
|2.04%||Guggenheim S&P Midcap 400 Pure Growth ETF (RFG)||+10.23 (9.43%)|
|0.6%||First Trust Mid Cap Core AlphaDEX (FNX)||+3.65 (8.10%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. Our key therapeutic products and product candidates include: º • º Prostacyclin Analogues. Prostacyclin analogues are stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function. Our lead product is Remodulin® (treprostinil) Injection (Remodulin), which is administered subcutaneously or intravenously for the treatment of pulmonary arterial hypertension (PAH). The United States Food and Drug Administration (FDA) initially approved Remodulin in 2002 for subcutaneous (under the skin) administration. ... More ...